Recursion Pharmaceuticals announced results of a clinical trial for its lead drug candidate Tuesday that, while a success on paper, likely won’t satisfy many investors closely watching the AI drug developer.
The Salt Lake City company’s treatment is for cerebral cavernous malformation, or CCM, a potentially life-threatening condition that causes vessels in the brain to become enlarged and irregular, sometimes causing blood to leak into the brain or spinal cord.
Recursion’s oral drug, called REC-994, achieved the primary goal of a year-long, 62-person Phase 2 study, proving safe and tolerable for patients compared to a placebo, the company said in a press release.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
